Biotech News

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind (MNKD)MannKind2026-06-25 13:46 ESTClinical readout

Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today

Open original release

Related news

MNKDMannKind2026-06-25 13:46 EST

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

MNKDMannKind2026-06-25 13:46 EST

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

MNKDMannKind2026-06-25 13:46 EST

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

MNKDMannKind2026-06-25 13:46 EST

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MNKDMannKind2026-06-25 13:46 EST

MannKind to Present at Jefferies Global Healthcare Conference

MNKDMannKind2026-06-25 13:46 EST

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

MNKDMannKind2026-06-25 13:46 EST

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

MNKDMannKind2026-06-25 13:46 EST

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

MNKDMannKind2026-06-25 13:46 EST

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

MNKDMannKind2026-06-25 13:46 EST

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

View all latest news

MannKind

MannKind is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

MNKDMannKind2026-06-26 07:29 EST

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

MNKDMannKind2026-06-26 07:29 EST

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

MNKDMannKind2026-06-26 07:29 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MNKDMannKind2026-06-26 07:29 EST

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

MNKDMannKind2026-06-26 07:29 EST

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States